LIBERATE NEWSLETTER

Vol 3/Issue 1 | April 2025

LIBERATE OBTAINS BRIDGE FUNDING

We are pleased to announce that the LIBERATE Study has received a $50,000 bridge funding grant from the River Philip Foundation at the University of Alberta. This additional funding will allow sites to continue recruitment through 2025.





FAQs

Q. A patient is on norepinephrine, epinephrine and vasopressin. How do we identify the peak dose? Doe the patient need to be weaning from ALL vasopressors or just one?

A. The patient must be weaning from all vasopressors. So each vasopressor would have to be at or below its highest level to be eligible.

Q. A patient was admitted with pneumospepsis and is developing an AKI. Is an AKI a contraindication to study enrollment?

A. AKI is not an exclusion to LIBERATE study enrollment.

Q. For exclusion #1 - > than 24 hours from peak dose – our patient's peak dose began at 11:00hrs but continued to 1400hrs. Do we count 24 hours from 11:00 or 14:00?

A. The peak starts at 1400 since that would be the highest value within the 24 hour window.

Study Coordinators Remember:

1. Enter new enrollments into the REDCap system as soon as possible to keep recruitment stats up to date.
2. Update your Screening Log and upload into your REDCap regulatory binder every month.

For more information contact:
Oleksa Rewa, Principal Investigator: rewa@ualberta.ca
Dawn Opgenorth,Project Manager: dawno@ualberta.ca
Or visit the LIBERATE Study website:
https://www.ualberta.ca/critical-care/research/liberate/index.html

The LIBERATE Study is supported by the Canadian Critical Care Trials Program Improvement and Integration Network, the Alberta Clinical Care Strategic Clinical Network, the University of Alberta and the University Hospital Foundation Medical Research and Kaye Fund

LIBERATE